Добірка наукової літератури з теми "Heart Effect of drugs on"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Heart Effect of drugs on".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

За допомогою хмари тегів ви можете побачити ще більше пов’язаних тем досліджень, а відповідні кнопки після кожного розділу сторінки дозволяють переглянути розширені списки книг, статей тощо на обрану тему.

Статті в журналах з теми "Heart Effect of drugs on":

1

Farrell, A. P., and M. S. Graham. "Effects of adrenergic drugs on the coronary circulation of Atlantic salmon (Salmo salar)." Canadian Journal of Zoology 64, no. 2 (February 1986): 481–84. http://dx.doi.org/10.1139/z86-071.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Spontaneously beating hearts from Atlantic salmon (Salmo salar) were used to examine the adrenergic regulation of the perfused coronary circulation. Excitatory α-adrenoceptors (vasoconstriction) dominated over inhibitory β-adrenoceptors (vasodilatation). Increased heart rate via β-adrenergic stimulation was possible with drug injections into the coronary artery. The heart rate effects followed the vasoactive effect by approximately 2 min.
2

Rorabaugh, Boyd R., Sarah L. Seeley, Albert D. Bui, Lisanne Sprague, and Manoranjan S. D'Souza. "Prenatal methamphetamine differentially alters myocardial sensitivity to ischemic injury in male and female adult hearts." American Journal of Physiology-Heart and Circulatory Physiology 310, no. 4 (February 2016): H516—H523. http://dx.doi.org/10.1152/ajpheart.00642.2015.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Methamphetamine is one of the most common illicit drugs abused during pregnancy. The neurological effects of prenatal methamphetamine are well known. However, few studies have investigated the potential effects of prenatal methamphetamine on adult cardiovascular function. Previous work demonstrated that prenatal cocaine exposure increases sensitivity of the adult heart to ischemic injury. Methamphetamine and cocaine have different mechanisms of action, but both drugs exert their effects by increasing dopaminergic and adrenergic receptor stimulation. Thus the goal of this study was to determine whether prenatal methamphetamine also worsens ischemic injury in the adult heart. Pregnant rats were injected with methamphetamine (5 mg·kg−1·day−1) or saline throughout pregnancy. When pups reached 8 wk of age, their hearts were subjected to ischemia and reperfusion by means of a Langendorff isolated heart system. Prenatal methamphetamine had no significant effect on infarct size, preischemic contractile function, or postischemic recovery of contractile function in male hearts. However, methamphetamine-treated female hearts exhibited significantly larger infarcts and significantly elevated end-diastolic pressure during recovery from ischemia. Methamphetamine significantly reduced protein kinase Cε expression and Akt phosphorylation in female hearts but had no effect on these cardioprotective proteins in male hearts. These data indicate that prenatal methamphetamine differentially affects male and female sensitivity to myocardial ischemic injury and alters cardioprotective signaling proteins in the adult heart.
3

Haverkamp, W. "Heart rate effects of antimuscarinic drugs." International Urology and Nephrology 51, no. 10 (July 2019): 1783–84. http://dx.doi.org/10.1007/s11255-019-02239-6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Girouard, Catherine, Jean-Pierre Grégoire, Paul Poirier, and Jocelyne Moisan. "Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure." Medicine 96, no. 9 (March 2017): e6239. http://dx.doi.org/10.1097/md.0000000000006239.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Nordin, Henrik, Anders M. Galløe, Søren D. Ladefoged, and Jørn Badskjær. "The effects of propranolol and verapamil on hyperthyroid heart symptoms and function, assessed by systolic time intervals." Acta Endocrinologica 128, no. 4 (April 1993): 297–300. http://dx.doi.org/10.1530/acta.0.1280297.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
The effects of acute and chronic administration of propranolol and verapamil on heart rate and systolic time intervals were studied in 10 hyperthyroid patients and 10 normal subjects, both groups without signs of cardiovascular or pulmonary disease. In normal subjects iv propranolol reduced heart rate significantly, and both drugs increased the total electromechanical systole significantly without difference between the drugs. This effect was insignificant when the drugs were given orally. In hyperthyroid patients both drugs reduced heart rate significantly in acute and chronic administration, and no difference between the two drugs was found. Neither drug altered cardiac contractility as assessed by systolic time intervals. These results indicate that the metabolic effects of thyroid hormone on contractility were unaltered and unblocked by the drugs. None of the participants developed signs of heart failure. Verapamil can thus be used as an alternative to propranolol in the treatment of tachycardia in hyperthyroidism.
6

Frigy, Attila, Márta Germán-Salló, Lehel Máthé, and Mónika Szabó. "Vércukorcsökkentő gyógyszerek biztonságossága szívelégtelenségben." Orvosi Hetilap 158, no. 5 (February 2017): 163–71. http://dx.doi.org/10.1556/650.2017.30652.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Abstract: The association of diabetes and heart failure is very common, furthermore, the pathophysiology and clinical course of the two entities have many crossing-points. Today, the spectrum of available anti-diabetic drugs is extremely wide, ranging from the classical (insulin, biguanides, sulphonylureas) to the most recent agents (gliptins, gliflozins). The cardiovascular effects of these drugs are multiple, their knowledge is important in the everyday practice, as the use of safe drugs regarding of heart failure is preferred. Our work provides an overview of each class of drugs after the presentation of the mechanism of action and the main representatives, the effects on the cardiovascular system, including those on heart failure will be described, mentioning the results of the most important clinical trials. The available data confirm the beneficial effects of metformin and gliflozins and the harmful effect of thiazolidinediones in heart failure. The other classes of drugs are permitted in heart failure, but it is important to continuously monitor the signs of decompensation. Orv. Hetil., 2017. 158(5), 163–171.
7

Gatzov, Plamen. "New glucose-lowering drugs in patients with heart failure." Bulgarian Cardiology 27, no. 2 (July 2021): 60–64. http://dx.doi.org/10.3897/bgcardio.27.e70144.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
The cardiovascular diseases are one of the main causes of mortality in the countries of Europe and North America. The heart failure (HF) and diabetes mellitus (DM) are widely spread diseases that become more frequent with the population aging in those regions. The algorithm of HF treatment in the last two decades includes several new medications. The SGLT-2 inhibitors (dapaglifl ozin, empaglifl ozin and canaglofl ozin) are new class anti diabetic medications which have positive effect on cardiovascular complications in patients with and without DB. The main trials using those medications in this group of patients and the most probable mechanisms, responsible for their effects, are the topic of this review.
8

Ritchie, Helen E., Isabelle Broström Huss, and William S. Webster. "The effect of anti-emetic drugs on rat embryonic heart activity." Reproductive Toxicology 87 (August 2019): 140–45. http://dx.doi.org/10.1016/j.reprotox.2019.06.002.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Ahmed, Mohamed Mahmoud, Muhammad Abdel-Gawad, Mahmoud Ahmed Abd elbaset, and Assem Elkady. "Effect of Direct Acting Anti-Hepatitis C Drugs on the Heart." Egyptian Journal of Hospital Medicine 82, no. 1 (January 2021): 106–14. http://dx.doi.org/10.21608/ejhm.2021.138116.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Fehér, Gergely, and Gabriella Pusch. "Role of antihypertensive drugs in the treatment of migraine." Orvosi Hetilap 156, no. 5 (February 2015): 179–85. http://dx.doi.org/10.1556/oh.2015.30056.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
The treatment of migraine depends on the frequency, severity and concomitant diseases. There are several specific drugs developed for migraine prevention in addition to the additive antimigraine effects of some other non-specific drugs. The aim of this literature-based review is to summarize the possible antimigraine properties of different antihypertensive agents (beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, etc.) focusing on the possible side effects (avoidance of beta blockers in the absence of heart disease, possible antiparkinson effect of calcium channel blockers, additive effect of drugs modifying the renin-angiotensin system activity, etc.). Current evidence supports the use of angiotensin converting enzyme inhibitors (mainly lisinopril) and angiotensin receptor blockers (mainly candesartan) for long-term migraine prevention and blood pressure control. Long-term beta-blocker treatment should be avoided in the absence of ischemic heart disease due to possible unfavourable cardiovascular effects. Orv. Hetil., 2015, 156(5), 179–185.

Дисертації з теми "Heart Effect of drugs on":

1

Zeitz, Christopher John. "Acute drug effects on the heart-haemodynamic, pharmacologic and metabolic correlations." Title page, contents and abstract only, 1999. http://web4.library.adelaide.edu.au/theses/09PH/09phz48.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Addenda and corrigenda inserted on verso of back end paper. Includes: Publications and communications to learned societies (p. 4-5). Bibliography: leaves 272-286. Examines the acute myocardial uptake of drugs, particularly perindoprilat and enalaprilat in humans. The uptake of these agents is examined, together with the haemodynamic, metabolic and biochemical effects. In particular, the impact of these agents on angiotensin and bradykinin peptides both within the heart and peripherally is described. The acute effects of a range of cardioactive drugs upon the left ventricular force-interval relationship is examined.
2

Maune, Jerene Mary 1953. "THE EFFECT OF CAFFEINE ON HEART RATE, RHYTHM AND BLOOD PRESSURE." Thesis-Reproduction (electronic), The University of Arizona, 1986. http://hdl.handle.net/10150/276372.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Ramadan, Waile Rushing Ann E. Hartberg W. Keith. "The protective effect of [alpha]-lipoic acid in doxorubicin induced cardiotoxicity in rats." Waco, Tex. : Baylor University, 2008. http://hdl.handle.net/2104/5218.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Li, Y. M. J. "An in-vivo study of the anti-arrhythmic and electrophysiological effects of amiodarone, lignocaine and penticainide (CM7857) in the rat." Electronic Thesis or Diss., De Montfort University, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.233821.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Huang, Yi Fei. "Myocardial pharmacokinetics and pharmacodynamics in the sheep /." Title page, contents and abstract only, 1991. http://web4.library.adelaide.edu.au/theses/09PH/09phh8742.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Thesis (Ph. D.)--University of Adelaide, Dept. of Anaesthesia and Intensive Care, 1992.
Accompanying diskette contains data of Chapters 3, 4, 5, 7, 8 and 9 (ASCII). Includes bibliographical references (leaves 177-207).
6

Ritchie, Rebecca Helen. "Acute haemodynamic effects of three cardioactive agents: metoprolol, sotalol and milrinone : influence of myocardial content and systolic interval /." Title page, table of contents and summary only, 1994. http://web4.library.adelaide.edu.au/theses/09PH/09phr611.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Shubat, Pamela Jane. "Monocrotaline toxicity and pulmonary arteries." Dissertation-Reproduction (electronic), The University of Arizona, 1988. http://hdl.handle.net/10150/184533.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Monocrotaline is a pyrrolizidine alkaloid found in plants implicated in livestock and human poisoning. Laboratory rats given monocrotaline develop pulmonary hypertension and right heart hypertrophy in the weeks following administration of the chemical. Lung weight increases and right heart hypertrophy correlate with increased pulmonary artery pressure. Rats which consumed monocrotaline drinking water (20 mg/l) for only 4 days developed significant increases in lung and heart weights 14 days after exposure began. This exposure was equivalent to a dose of 15 mg/kg. Other treatment combinations of time (0-10 days exposure) and monocrotaline concentration (5-60 mg/l in drinking water) were tested. The accumulative dose calculated for each of the treatment combinations which produced toxicity was in the range of 15 to 20 mg/kg. Monocrotaline injury appears to be cumulative, but organ weight increases reverse once exposure is stopped. As pulmonary hypertension develops and pulmonary arteries hypertrophy, the force with which isolated pulmonary artery segments contract decreases. This is a loss of efficacy rather than potency to the contracting agents KCl, norepinephrine, and 5-hydroxytryptamine. Relaxation of arteries under conditions of potassium-return (a measure of Na⁺/K⁺ ATPase activity) was also altered by monocrotaline treatment. In vivo monocrotaline treatment had little effect on the force of K⁺-return relaxation. However, the rate at which arteries relaxed was significantly decreased following 4 days ingestion of monocrotaline drinking water (20 mg/l). In vitro ouabain treatment and endothelial injury also decreased the rate of K⁺-return relaxation. Another Na⁺/K⁺ ATPase activity, ⁸⁶Rb⁺ uptake, was decreased following monocrotaline treatment only when 5-hydroxytryptamine was present and only uptake associated with the endothelium was affected. These studies utilized a very low exposure to monocrotaline (4 days ingestion of 20 mg/l monocrotaline drinking water or 15 mg/kg) to produce toxicity in rats. Monocrotaline-induced toxicity measured 20 days after treatment included right heart and lung hypertrophy and decreased contractions of isolated pulmonary arteries. Monocrotaline treatment decreased the rate of Na⁺/K⁺ ATPase-dependent relaxation of isolated pulmonary arteries 4 days after treatment began.
8

Rossouw, Ellen. "The effect of androgenic anabolic steroids on the susceptibility of the rat heart to ischaemia and reperfusion injury." Thesis, Stellenbosch : Stellenbosch University, 2002. http://hdl.handle.net/10019.1/53105.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Thesis (MSc)--University of Stellenbosch, 2002.
ENGLISH ABSTRACT: Background: Athletes use androgenic anabolic steroids (AAS) to enhance their physical performance. The abuse of AAS is however associated with a host of side effects including sudden death due to cardiac arrest. The use of AAS leads to myocardial hypertrophy, which possibly makes the heart more prone to ischaemia/reperfusion injury, since it often develops in the absence of proper vasculature development. Chronic AAS use also disrupts myocardial p-adrenoreceptor function and possibly cAMP, signalling in the heart. Drugs increasing cAMP and decreasing cGMP levels in the ischaemic myocardium exacerbate myocardial ischaemia/reperfusion injury. We also know that AAS causes coronary artery disease secondary to the deleterious alteration of lipid profiles by increasing the LOL cholesterol and decreasing the HOLcholesterol levels. AAS treatment may increase systemic TNFa levels by stimulating lymphocyte TNFa secretion that has been implicated in the depression of myocardial function, myocardial hypertrophy and the worsening of ischaemia/reperfsuion injury. Aims: To determine whether chronic AAS treatment in trained and untrained rats influences: 1) heart function and susceptibility to ischaemia/reperfusion injury, 2) myocardial cyclic nucleotide levels (cAMP and cGMP) and 3) myocardial TNFa levels. Material and methods: Male Sprague-Dawley rats (n=100) were divided into 4 groups: sedentary vehicle (placebo) treated group, sedentary AAS treated group, exercise vehicle (placebo) treated group, and exercise AAS treated group. Steroid treated animals received an intramuscular injection of nandrolone laureate (0.375 mg/kg) once a week, for six weeks. Training consisted of swim sessions 6 days a week for 6 weeks. Swim time was incrementally increased up to a maximum of 50 minutes a day. For biometric parameters heart weight and body weight were documented. Hearts were mounted on a l.anqendorff perfusion apparatus and left ventricular developed pressure (LVDP), heart rate (HR) and coronary flow (CF) was monitored. The hearts were subjected to a period of 20 minutes of global ischaemia, followed by 30 minutes of reperfusion. Functional parameters was again monitored and documented. For biochemical analysis, blood was collected for the determination of serum lipid levels and myocardial tissue samples were collected before, during and after ischaemia for the determination of myocardial TNFa, cGMP and cAMP levels and p38 activity. Conclusions: Results obtained would suggest that AAS exacerbate exercise induced myocardial hypertrophy. It also prevents the exercise-induced improvement in cardiac function. AAS use reduces reperfusion function in treated hearts, which may suggest that AAS exacerbates ischaemie and reperfusion injury. Furthermore it was seen that AAS elevates basal (preischaemie) cyclic nucleotide levels and basal (pre-ischaemic) as well as reperfusion TNFa levels. This may also contribute to the exacerbation of ischaemic and reperfusion injury.
AFRIKAANSE OPSOMMING: Agtergrond: Androgeniese anaboliese steroïede (AAS) word dikwels deur atlete gebruik om sportprestasie te verbeter. Die misbruik van AAS het egter talle newe effekte, insluitende skielike dood wat gewoonlik toegeskryf word aan hartaanvalle. Die gebruik van AAS lei onder andere tot miokardiale hipertrofie wat opsigself, as gevolg van ontoereikende vaskulêre ontwikkeling tydens die ontwikkeling van hipertrofie, die hart nog meer vatbaar vir isgemie/herperfusie skade maak. Kroniese AAS toediening versteur miokardiale beta-adtenoresepter funksie en moontlik die tweede boodskapper, sAMP, seintransduksie in die hart. Ons weet ook dat AAS koronêre hartvatsiektes veroorsaak. Laasgenoemde is sekondêr tot die nadelige lipiedprofiel verandering, wat 'n verhoging in LDL-C en 'n verlaging in HDL-C insluit. Middels wat miokardiale sAMP vlakke verhoog en sGMP vlakke in die isgemiese miokardium verlaag, vererger miokardiale isgemie/herperfusie skade. AAS behandeling kan moontlik ook sistemiese TNFa vlakke verhoog deur limfosiet TNFa sekresie te stimuleer. Die verhoogde TNFa vlakke word verbind aan die onderdrukking van miokardiale funksie, miokardiale hipertrofie en die verergering van isgemie/herperfusie skade. Doelwitte: Die doelwitte van die studie was om te bepaal of kroniese AAS toediening in geoefende en ongeoefende rotte 1) hartfunksie en die hart se vatbaarheid vir isgemie/herperfusie skade beïnvloed, 2) miokardiale sikliese nukleotiedvlakke (sAMP en sGMP) beïnvloed en 3) miokardiale TNFa-vlakke beïnvloed. Materiale en metodes: Manlike Sprague-Dawley rotte (n=100) is gebruik en in 4 groepe verdeel: 'n ongeoefende placebo groep (kontrole); 'n ongeoefende steroïedbehandelde groep; 'n geoefende placebo groep (kontrole) en 'n geoefende steroïedbehandelde groep. Steroïed behandelde diere het 'n intramuskulêre nandroloon lauraat inspuiting (0.375 mg/kg) een keer per week vir ses weke ontvang. Die oefenprogram het bestaan uit ses swemsessies 'n week vir ses weke. Die swemtyd is geleidelik weekliks verhoog tot by 'n maksimum tyd 50 min. Die waterbadtemperatuur is tussen 30 - 32 oe gehandhaaf. Vir biometriese parameters is hartgewig en liggaamsgewig genoteer. Harte is op 'n Langendorff perfusie apparaat gemonteer en linker ventrikulêre ontwikkelde druk (LVOD), koronêre vloei (KV) en harttempo (HT) is genoteer. Die harte is vervolgens blootgestel aan 20 minute van globale isgemie gevolg deur 'n 30 minute herperfusieperiode. LVOD, KV en HT is weer eens noteer. Vir biochemiese doeleindes is bloed voor perfusie versamelom serum lipied vlakke te bepaal. Miokardiale weefsel is versamel voor, tydens en na isgemie vir die bepaling van TNFa, cGMP en AMP vlakke asook p38 aktiwiteit. Gevolgtrekkings: Na aanleiding van resultate verkry wil dit voorkom asof die gebruik van steroïde oefeningsgeïnduseerde miokardiale hipertrofie vererger. Dit verhoed ook oefeningsgeïnduseerde verbetering in miokardiale funksie. AAS lei tot 'n verlaagde herperfusiefunksie in behandelde harte, wat dalk mag dui op MS verergering van isgemie en herperfusie skade. Verder was daar ook waargeneem dat MS basale (pre-isgemiese) sikliese nukleotiedvlakke en basale TNFa-vlakke sowel as herperfusie TNFa vlakke verhoog. Die verhoging in TNF-a vlakke mag dus moontlik ook bydra tot die verergering van isgemie- en herperfusieskade.
9

Leigh, Felicity Suzanne Marshall. "The effects of diet, anorectic drugs and caffeine on various cardiovascular parameters in the rat." Electronic Thesis or Diss., University of Bath, 1988. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.382595.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Kalis, Joni Kathryn. "THE EFFECT OF BETA-ADRENERGIC BLOCKADE ON THE DRIFT IN OXYGEN CONSUMPTION WITH PROLONGED EXERCISE." Thesis-Reproduction (electronic), The University of Arizona, 1985. http://hdl.handle.net/10150/292014.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Книги з теми "Heart Effect of drugs on":

1

Droogmans, Steven. Drug-induced valvular heart disease. Hauppauge, N.Y: Nova Science Publishers, 2010.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Gavin, Katherine T. Investigations of cardiovascular [alpha]-adrenoceptor function. Dublin: University College Dublin, 1997.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Myers, Adam K., and Ronald R. Watson. Alcohol and heart disease. London: Taylor & Francis, 2003.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Ewer, Michael S. Cancer and the heart. Hamilton. ON: BC Decker Inc., 2007.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

International, Symposium on the Organ Directed Toxicities of Anticancer Drugs (1st 1987 Burlington Vt ). Organ directed toxicities of anticancer drugs: Proceedings of the First International Symposium on the Organ Directed Toxicities of Anticancer Drugs, Burlington, Vermont, USA, June 4-6, 1987. Boston: Nijhoff, 1988.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Haiat, Robert. Major clinical trials in cardiovascular therapeutics: 1995-2000 /$cRobert Haïat, Gérard Leroy ; reviewed by Anthony Saul ; preface by P. Théroux. Paris: Frison-Roche, 2001.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Kaski, Juan Carlos, and Stuart Baker. Drugs in cardiology: A comprehensive guide to cardiovascular pharmacotherapy. Oxford: Oxford University Press, 2010.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

(Germany)), Freiburg Focus on Biomeasurement (9th 1995 Freiburg im Breisgau. Pharmacological evaluation of cardioprotective substances: Experimental induction and indicators of myocardial injury and myocardial protection. Buchenbach, Germany: Gesellschaft für Erfahrungstransfer in der Biomesstechnik e.V., 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Brown, Hilary. Physiology and pharmacology of the heart. Oxford [England]: Blackwell Science, 1997.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Turner, J. Rick. Integrated cardiac safety: Assessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance. Hoboken, N.J: John Wiley & Sons, 2009.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Heart Effect of drugs on":

1

Schwandt, Peter, Markus G. Donner, and Werner O. Richter. "Long-Term Effect of Ldl-Apheresis on Coronary Heart Disease." In Drugs Affecting Lipid Metabolism, 513–19. Dordrecht: Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-009-0311-1_60.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Pugliese, Anna Maria, Elisabetta Coppi, Federica Cherchi, and Giancarlo Pepeu. "Cardiovascular Adverse Effects of Psychotropic Drugs." In Brain and Heart Dynamics, 1–15. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-90305-7_45-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Pugliese, Anna Maria, Elisabetta Coppi, Federica Cherchi, and Giancarlo Pepeu. "Cardiovascular Adverse Effects of Psychotropic Drugs." In Brain and Heart Dynamics, 707–20. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-28008-6_45.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Yang, Charles I., Pravin Taneja, and Peter J. Davis. "Sedative Hypnotic and Anesthetic Agents: Their Effect on the Heart." In Handbook of Pediatric Cardiovascular Drugs, 280–317. London: Springer London, 2008. http://dx.doi.org/10.1007/978-1-84628-953-8_12.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Govoni, S. "Psychiatric and Neurological Effects of Cardiovascular Drugs." In Brain and Heart Dynamics, 1–14. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-319-90305-7_46-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Govoni, Stefano. "Psychiatric and Neurological Effects of Cardiovascular Drugs." In Brain and Heart Dynamics, 731–44. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-28008-6_46.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Erlemeier, H. H., and W. Bleifeld. "Effects of Different Positive Inotropic Drugs in Congestive Heart Failure." In Heart Failure Mechanisms and Management, 205–10. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-58231-8_21.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Asteggiano, Riccardo. "Physiopathology and Toxic Heart Effects of Chemotherapy Drugs." In Cardiac Management of Oncology Patients, 23–97. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-15808-2_2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Gupta, Suresh Kumar, Meenu Sharma, Ipseeta Mohanty, and Dharamvir S. Arya. "Molecular Basis for the Cardioprotective Effect of Herbal Drugs in Ischemic Heart Disease: An Experimental Study." In Myocardial Ischemia and Preconditioning, 235–48. Boston, MA: Springer US, 2003. http://dx.doi.org/10.1007/978-1-4615-0355-2_17.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Eriksson, L. O., B. Beermann, and M. Kallner. "Aspects of the Effects or NSAID’s on Renal Function in Congestive Heart Failure." In Non-steroidal Anti-Inflammatory Drugs Basis for Variability in Response, 99–103. Basel: Birkhäuser Basel, 1985. http://dx.doi.org/10.1007/978-3-0348-7720-6_12.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Heart Effect of drugs on":

1

Serša, Gregor. "CLINICAL APPLICATIONS OF ELECTROCHEMOTHERAPY." In Symposium with International Participation HEART AND … Akademija nauka i umjetnosti Bosne i Hercegovine, 2019. http://dx.doi.org/10.5644/pi2019.181.01.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Electroporation has several biomedical and industrial applications. The biomedical applications are in the field of drug or gene delivery. Electrochemotherapy utilizes electroporation for the increased delivery of cytotoxic drugs like bleomycin or cisplatin into tumors. The use of electrochemotherapy has spread throughout Europe for the treatment of cutaneous tumors or metastases. It is in the NICE guidelines and is becoming standard ablative technique in treatment of cancer. The technological advancements have also enabled the use of electrochemotherapy for the treatment of deep seated tumors, such as soft tissue or liver tumors. Clinical studies demonstrate good effectiveness on fibrosarcomas, colorectal liver metastases and hepatocellular carcinoma. However, electrochemotherapy is a local treatment that also induces moderate local immune response. This so called “in situ vaccination” induced by electrochemotherapy can be exploited in combined treatment with immune checkpoint inhibitors or electrogene therapy with immunostimulating effect. Therefore, gene electrotransfer of plasmid coding for interleukin 12 (IL-12), in combination with electrochemotherapy could result in transformation of electrochemotherapy from local into systemic treatment. This is also of our current interest, and we are undertaking steps to bring this idea from preclinical into clinical testing.
2

Moussa, Heba Adel Mohamed Lotfy, Gawaher Saleh Abbas Mahgoub, Mashael Ali H. I. Al-Badr, and Huseyin Cagatay Yalcin. "Investigating the Cardiac Effects of Sildenafil loaded Nanoparticles on Heart Failure using the Zebrafish Embryo Model." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0217.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Background: Cardiovascular diseases (CVDs) are the first cause of death worldwide. Vasolidator agents are used to relax cardiac muscle, but their extremely short half-lifes limit their effectiveness. Sildenafil is such an agent used to relax the blood vessels muscles and increase the blood flow. The conventional drug can lead to serious problems in patients duo to the systematic drug delivery. Use of Nanomedicine potentially can enhance delivery of this agent while reducing the systematic effect of the drug. Aim: The purpose of the research is to examine the effectiveness sildenafil loaded nanoparticles in rescuing heart failure using zebrafish embryo model. Methods: There will be five experimental groups. The zebrafish will be treated with Aristolochic Acid (AA) at 24 hour per fertilization (hpf) to create the heart injury group. The treatment groups will be heart injury followed by a dose of either Sildenafil or Sildenafil loaded nanoparticles at 36 hpf. Two control groups will be the negative control (exposed to egg water) and vehicle control (exposed to the Dimethylsulfoxide (DMSO)).To evaluate the drug effects on embryo, toxicity assessment (Survival rate, tail flicking and hatching rate), cardiotoxicity assessment and gene expression of heart injury marker via RT-PCR will be conducted. Results: Preliminary findings demonstrate, loading Sildenafil to nanoparticles enhances its effectiveness dramatically. The experiments are ongoing to confirm the results. Conclusion: Nanomedicine is a powerful approach to enhance cardiovascular therapy. Vasodilator drugs in particular will benefit from this improvement as demonstrated with our findings
3

Alkawari, Fatima, Wigdan Ali, Fatiha Benslimane, and Huseyin Yalcin. "Investigating the Cardiac effects of New Generation Anti-Diabetic Drug Empagliflozin using Zebrafish Embryo Model." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0211.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Type 2 diabetes mellitus (T2DM) affects >16% of adults in Qatar. Newly emerging class of antidiabetic drugs focused on SGLT inhibition were observed to reduce CVDs risks in diabetic patients. Up to date, the mechanism contributing to the CV benefits remains unrevealed. Zebrafish embryos were treated with Aristolochic Acid to induce heart failure then treated with Empagliflozin to determine its beneficial effect. Furthermore the expression of SGLT1 & 2 were determined in the hearts of zebrafish. SGLT2 was expressed more then SGLT1 in the heart and whole embryo. Empa significantly improved the zebrafish embryo'scardiachealthafterinductionofheartfailure.
4

Haddad, Batoul, Zainab El-hashmi, Huseyin Yalcin, Fatiha Benslimane, and Hana A. Hussain. "Investigating the Efficacy of Natural Blood Glucose Lowering Compounds in the Prevention of Congenital Heart Defects during Maternal Diabetes using the Chick Embryo." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0195.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Diabetes is a metabolic disorder that is characterized by hyperglycemia. Although there are several drugs available for diabetes, patients tend to follow natural remedies. However, the use of these natural remedies lacks scientific evidence of its effect. Therefore, the aim of this project was to first identify the histological changes of the developing heart in a hyperglycemic environments. Secondly, test the efficacy of selected natural compounds in lowering blood glucose levels and to assess its gene expression changes.
5

McGoron, Anthony J., and Alicia Fernandez-Fernandez. "Development of a Multiple Indicator Dilution Technique Using Fluorescent Dyes to Measure Cardiac Capillary Permeability." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192955.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Anthracyclines are widely-used drugs for the treatment of cancer. Although these drugs are effective in reducing or containing tumor progress, their long-term use is limited by toxicity effects. A special area of concern is related to the toxic effects that these drugs have on the myocardial tissue, including interstitial edema, fibrosis, degeneration of myocardial cells, and cardiac dilatation, among others. The end result is an overall impairment in cardiac function that limits the use of these agents [1,2]. This damage in heart function can be life-threatening, and it causes special concern in patients with prior cardiac dysfunction, as well as in children [2]. As a result of these disadvantages, there is a trend in current research to develop anthracycline derivatives or modified formulations with reduced cardiotoxic effects, as well as to learn more of the mechanisms that mediate this cardiac toxicity. Our long-term goal is to measure changes in capillary endothelium permeability in the heart after administration of anthracyclines which may contribute to the overall deterioration in function observed after chronic treatment with this medication. The goal of this project was to develop a sensitive, non-radioactive technique to measure capillary permeability in experimental animal models. This technique could then be applied in future studies of anthracycline cardiotoxicity.
6

Al-Ansari, Dana E., Nura A. Mohamed, Isra Marei, Huseyin Yalcin, and Haissam Abou-Saleh. "Assessment of Metal Organic Framework as Potential Drug Carriers in Cardiovascular Diseases." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0127.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Background: Cardiovascular diseases (CVDs) are considered the major cause of death worldwide. Therapeutic delivery to the cardiovascular system may play an important role in the successful treatment of a variety of CVDs, including atherosclerosis, ischemic-reperfusion injury, and microvascular diseases. Despite their clinical benefits, current therapeutic drugs are hindered by their short half-life and systemic side effects. This limitation could be overcome using controlled drug release with the potential for targeted drug delivery using a nanomedicine approach. In the current study, we have assessed the use of a highly porous nano-sized preparation of iron-based Metal-organic Framework (MOF) commonly referred to as MIL-89 as potential drug carriers in the cardiovascular system. Aims: To assess the effect of MOFs on the viability and cytotoxicity of human vascular cells and the cellular uptake in vitro, and the organ-system toxicity of MOF in vivo using the Zebrafish model. Methods: Human pulmonary endothelial cells (HPAECs) and pulmonary smooth muscle cells (HPASMCs) were treated with variable concentrations of MOFs. The viability, cytotoxicity and anti-inflammatory effects were measured using AlamarBlue, LDH assay and ELISA. The cellular uptake of MOFs were assessed using light, confocal, and transmission electron microscopes and EDS analysis. Moreover, Zebrafish embryos were cultured and treated with MOFs-nanoparticles at 0 hours post fertilization (hpf) followed by different organ-specific assays at 24, 48, and 72 hpf. Results: Although MOFs affect the viability at high concentrations, it does not cause any significant cytotoxicity on HPAECs and HPASMCs. Interestingly, MOFs were shown to have an anti-inflammatory effect. Microscopic images showed an increased (concentration-dependent) cellular uptake of MOFs and transfer to daughter cells in both cell types. Moreover, the in vivo study showed that high concentrations of MOFs delay zebrafish embryos hatching and cause heart deformation, which is currently investigated using cardiotoxicity markers. Conclusion: MOFs is a promising nanoparticle prototypes for drug delivery in the cardiovascular system with high cellular uptake and anti-inflammatory effects. Further investigations of MOFs, including diseased models and drug- loaded formulation is required.
7

Da Silva, Alberto Vianna Dias, and Vaninha Vieira. "BBAware - A Context-Aware Mobile and Wearable Architecture for Monitoring Beta-Blocked Cardiac Patients." In VIII Simpósio Brasileiro de Computação Ubíqua e Pervasiva. Sociedade Brasileira de Computação - SBC, 2020. http://dx.doi.org/10.5753/sbcup.2016.9444.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Beta-blockade drugs are still in use as treatment option to lower heart rate, to improve cardiac function, and to reduce cardiovascular events. Patients who use beta-blockers usually surpass a therapeutic test full of collateral effects to adapt their organisms. Furthermore, these patients with a baseline heart rate above 70 beats per minute have a significantly higher risk of all cardiovascular events. Context-aware healthcare field arises as an alternative to monitor patients constantly. This paper introduces the Beta-Blocked Aware (BBAware) project, a pervasive solution, that uses the concepts of ubiquitous healthcare in order to help patients under beta-blockade treatments.
8

Widiawaty, Candra Damis, Ahmad Indra Siswantara, Budiarso, Asyari Daryus, Gun Gun Ramdlan Gunadi, and Hariyotejo Pujowidodo. "Investigation the effect of superficial velocity to the heat transfer in bubbling regime of fluidization using CFD simulation." In THE 4TH BIOMEDICAL ENGINEERING’S RECENT PROGRESS IN BIOMATERIALS, DRUGS DEVELOPMENT, HEALTH, AND MEDICAL DEVICES: Proceedings of the International Symposium of Biomedical Engineering (ISBE) 2019. AIP Publishing, 2019. http://dx.doi.org/10.1063/1.5138279.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Kusuma, Mukhsinun Hadi, Mulya Juarsa, Nandy Putra, Anhar Riza Antariksawan, Muhammad Subekti, and Surip Widodo. "The filling ratio effect on the overshoot phenomenon of vertical straight wickless-heat pipe with low temperature source." In THE 4TH BIOMEDICAL ENGINEERING’S RECENT PROGRESS IN BIOMATERIALS, DRUGS DEVELOPMENT, HEALTH, AND MEDICAL DEVICES: Proceedings of the International Symposium of Biomedical Engineering (ISBE) 2019. AIP Publishing, 2019. http://dx.doi.org/10.1063/1.5135527.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Bagge, L., E. Holmer, S. O. Nystroöm, H. Tydeén, and T. Wahlberg. "FRAGMIN VS HEPARIN AT RECYCLING OE HUMAN BLOOD IN HEART-LUNG MACHINE (HLM)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643042.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
During cardio-pulmonary bypass (CPB), Heparin inhibits EXa (EXal), thrombin and platelet activity and is also reported to induce fibrinolysis. Eragmin (Erag) has 25% thrombin inhibition capacity as related to that of Heparin (Hep). An in_vitro study was performed to compare Frag with Hep by circulating blood in a pure artificial system. In 20 experiments, 400 ml of freshly collected blood with Frag or Hep were recycled for 2 h. HLM was primed with 400 ml of Ringeracetate. Blood sampling: donor, blood pack and every 20 min from the oxygenator. V_a£i£ble£/jassay/:ACT/Hemochron/5 APTT , TT and NT/Nyegaard/;FXaI, FVIII and ATIiT t"ATA)/amydolytic/; AT 111 (ATAg) and vWF/IEP/;Plasminogen (Pig) and albumine/immuno-diffusion/;FDP/Wellcome/;Platelet function/Adeplat S/;Fibrinogen (Fbg)/clottable/;Hemolysis (HL)/photometric/; (β -Thromboglobulin ((βTG)/RTA/;EVF, Hb, platelet count (PC) and Leucocyte count (LC)/ conventional). Corrections for hemo-/plasma dilutions were calculated. Dosages (n): Frag: 750 (1), 1500 (3), 2100 (4), 2500 (4) FXal-U (U); Hep: 1000 (3), 1500 (6) IU clinical level. Clotting only occurred at Frag 750 (1) and 1500 (2) U, when ACT, APTT, FVIII, Fbg and ATA were significantly lowered. Generally, PC fell 75% during the recycling, while PF was constant'∼20% and (βTG increased. Neither presence of FDP nor Pig consumption were detected. FXal, ACT, APTT, TT and NT were dose dependent for both drugs. ATA was directly dose-related to Frag but inversely to Hep. LC decreased with the Frag-dose but inversely to that of Hep. HL increased generally. Several proteins increased (clotting excl): Fbg 30%, ATAg 25%, ATA 45?o and vWF 60%. Conclusions. Prevention of clotting required about the double dosage of Frag. Shortened ACT and APTT predicted clotting while the levels of FXal, TT and NT did not. Thus, an effective thrombin inhibition is needed under this conditions. Consumptions of FVIII, Fbg and ATA but no further drop in PC at clotting, indicate weak platelet aggregation involvement. Absence of fibrinolytic signs supports that the fibrinolysis seen at CPB, is not a genuine effect of Hep (or Frag). Increases in some proteins may be caused by cytolysis. The rise in vWF is probably due to release from platelet surfaces.

Звіти організацій з теми "Heart Effect of drugs on":

1

Black, Sandra, Paul Devereux, and Kjell Salvanes. Losing Heart? The Effect of Job Displacement on Health. Cambridge, MA: National Bureau of Economic Research, December 2012. http://dx.doi.org/10.3386/w18660.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Lichtenberg, Frank. The Effect of New Drugs on Mortality from Rare Diseases and HIV. Cambridge, MA: National Bureau of Economic Research, December 2001. http://dx.doi.org/10.3386/w8677.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Crosland, Richard D. Effect of Drugs on the Lethality in Mice of the Venoms and Neurotoxins from Sundry Snakes. Fort Belvoir, VA: Defense Technical Information Center, July 1990. http://dx.doi.org/10.21236/ada228245.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Georgitsis, Micheal. The Effect of Lymph Sac Pressure on Lymph Heart Pressure Development in the Toad Bufo Marinus. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.7232.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Lleras-Muney, Adriana, and Frank Lichtenberg. The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs. Cambridge, MA: National Bureau of Economic Research, September 2002. http://dx.doi.org/10.3386/w9185.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Treadwell, Jonathan R., James T. Reston, Benjamin Rouse, Joann Fontanarosa, Neha Patel, and Nikhil K. Mull. Automated-Entry Patient-Generated Health Data for Chronic Conditions: The Evidence on Health Outcomes. Agency for Healthcare Research and Quality (AHRQ), March 2021. http://dx.doi.org/10.23970/ahrqepctb38.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Background. Automated-entry consumer devices that collect and transmit patient-generated health data (PGHD) are being evaluated as potential tools to aid in the management of chronic diseases. The need exists to evaluate the evidence regarding consumer PGHD technologies, particularly for devices that have not gone through Food and Drug Administration evaluation. Purpose. To summarize the research related to automated-entry consumer health technologies that provide PGHD for the prevention or management of 11 chronic diseases. Methods. The project scope was determined through discussions with Key Informants. We searched MEDLINE and EMBASE (via EMBASE.com), In-Process MEDLINE and PubMed unique content (via PubMed.gov), and the Cochrane Database of Systematic Reviews for systematic reviews or controlled trials. We also searched ClinicalTrials.gov for ongoing studies. We assessed risk of bias and extracted data on health outcomes, surrogate outcomes, usability, sustainability, cost-effectiveness outcomes (quantifying the tradeoffs between health effects and cost), process outcomes, and other characteristics related to PGHD technologies. For isolated effects on health outcomes, we classified the results in one of four categories: (1) likely no effect, (2) unclear, (3) possible positive effect, or (4) likely positive effect. When we categorized the data as “unclear” based solely on health outcomes, we then examined and classified surrogate outcomes for that particular clinical condition. Findings. We identified 114 unique studies that met inclusion criteria. The largest number of studies addressed patients with hypertension (51 studies) and obesity (43 studies). Eighty-four trials used a single PGHD device, 23 used 2 PGHD devices, and the other 7 used 3 or more PGHD devices. Pedometers, blood pressure (BP) monitors, and scales were commonly used in the same studies. Overall, we found a “possible positive effect” of PGHD interventions on health outcomes for coronary artery disease, heart failure, and asthma. For obesity, we rated the health outcomes as unclear, and the surrogate outcomes (body mass index/weight) as likely no effect. For hypertension, we rated the health outcomes as unclear, and the surrogate outcomes (systolic BP/diastolic BP) as possible positive effect. For cardiac arrhythmias or conduction abnormalities we rated the health outcomes as unclear and the surrogate outcome (time to arrhythmia detection) as likely positive effect. The findings were “unclear” regarding PGHD interventions for diabetes prevention, sleep apnea, stroke, Parkinson’s disease, and chronic obstructive pulmonary disease. Most studies did not report harms related to PGHD interventions; the relatively few harms reported were minor and transient, with event rates usually comparable to harms in the control groups. Few studies reported cost-effectiveness analyses, and only for PGHD interventions for hypertension, coronary artery disease, and chronic obstructive pulmonary disease; the findings were variable across different chronic conditions and devices. Patient adherence to PGHD interventions was highly variable across studies, but patient acceptance/satisfaction and usability was generally fair to good. However, device engineers independently evaluated consumer wearable and handheld BP monitors and considered the user experience to be poor, while their assessment of smartphone-based electrocardiogram monitors found the user experience to be good. Student volunteers involved in device usability testing of the Weight Watchers Online app found it well-designed and relatively easy to use. Implications. Multiple randomized controlled trials (RCTs) have evaluated some PGHD technologies (e.g., pedometers, scales, BP monitors), particularly for obesity and hypertension, but health outcomes were generally underreported. We found evidence suggesting a possible positive effect of PGHD interventions on health outcomes for four chronic conditions. Lack of reporting of health outcomes and insufficient statistical power to assess these outcomes were the main reasons for “unclear” ratings. The majority of studies on PGHD technologies still focus on non-health-related outcomes. Future RCTs should focus on measurement of health outcomes. Furthermore, future RCTs should be designed to isolate the effect of the PGHD intervention from other components in a multicomponent intervention.
7

Xu, Jian-bo. Effect of grelin on TRX expression in chronic heart failure tissue: a protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review Protocols, April 2020. http://dx.doi.org/10.37766/inplasy2020.4.0078.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Chou, Roger, Jesse Wagner, Azrah Y. Ahmed, Ian Blazina, Erika Brodt, David I. Buckley, Tamara P. Cheney, et al. Treatments for Acute Pain: A Systematic Review. Agency for Healthcare Research and Quality (AHRQ), December 2020. http://dx.doi.org/10.23970/ahrqepccer240.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Objectives. To evaluate the effectiveness and comparative effectiveness of opioid, nonopioid pharmacologic, and nonpharmacologic therapy in patients with specific types of acute pain, including effects on pain, function, quality of life, adverse events, and long-term use of opioids. Data sources. Electronic databases (Ovid® MEDLINE®, PsycINFO®, Embase®, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews) to August 2020, reference lists, and a Federal Register notice. Review methods. Using predefined criteria and dual review, we selected randomized controlled trials (RCTs) of outpatient therapies for eight acute pain conditions: low back pain, neck pain, other musculoskeletal pain, neuropathic pain, postoperative pain following discharge, dental pain (surgical or nonsurgical), pain due to kidney stones, and pain due to sickle cell disease. Meta-analyses were conducted on pharmacologic therapy for dental pain and kidney stone pain, and likelihood of repeat or rescue medication use and adverse events. The magnitude of effects was classified as small, moderate, or large using previously defined criteria, and strength of evidence was assessed. Results. One hundred eighty-three RCTs on the comparative effectiveness of therapies for acute pain were included. Opioid therapy was probably less effective than nonsteroidal anti-inflammatory drugs (NSAIDs) for surgical dental pain and kidney stones, and might be similarly effective as NSAIDs for low back pain. Opioids and NSAIDs were more effective than acetaminophen for surgical dental pain, but opioids were less effective than acetaminophen for kidney stone pain. For postoperative pain, opioids were associated with increased likelihood of repeat or rescue analgesic use, but effects on pain intensity were inconsistent. Being prescribed an opioid for acute low back pain or postoperative pain was associated with increased likelihood of use of opioids at long-term followup versus not being prescribed, based on observational studies. Heat therapy was probably effective for acute low back pain, spinal manipulation might be effective for acute back pain with radiculopathy, acupressure might be effective for acute musculoskeletal pain, an opioid might be effective for acute neuropathic pain, massage might be effective for some types of postoperative pain, and a cervical collar or exercise might be effective for acute neck pain with radiculopathy. Most studies had methodological limitations. Effect sizes were primarily small to moderate for pain, the most commonly evaluated outcome. Opioids were associated with increased risk of short-term adverse events versus NSAIDs or acetaminophen, including any adverse event, nausea, dizziness, and somnolence. Serious adverse events were uncommon for all interventions, but studies were not designed to assess risk of overdose, opioid use disorder, or long-term harms. Evidence on how benefits or harms varied in subgroups was lacking. Conclusions. Opioid therapy was associated with decreased or similar effectiveness as an NSAID for some acute pain conditions, but with increased risk of short-term adverse events. Evidence on nonpharmacological therapies was limited, but heat therapy, spinal manipulation, massage, acupuncture, acupressure, a cervical collar, and exercise were effective for specific acute pain conditions. Research is needed to determine the comparative effectiveness of therapies for sickle cell pain, acute neuropathic pain, neck pain, and management of postoperative pain following discharge; effects of therapies for acute pain on non-pain outcomes; effects of therapies on long-term outcomes, including long-term opioid use; and how benefits and harms of therapies vary in subgroups.
9

Guan, Hui, Guohua Dai, Ning Wang, Wulin Gao, Lili Ren, and Zhenhao Cai. Effect and Safety of Oral Chinese Patent Medicine for Heart Failure: A protocol for systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2020. http://dx.doi.org/10.37766/inplasy2020.9.0053.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Brown, Michael. Effect of Ototoxic Drugs on the Amphibian Auditory System: Injection of Gentamicin Sulfate into Anuran Otic Capsules and Recovery of Thresholds. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.6734.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

До бібліографії
Current page language: Ukrainian.
You might want to see the page in this language: English.
Change language